{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:38:24Z","timestamp":1785465504999,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"SENDIMAD","award":["BECA SENDIMAD de Ayuda a la Investigaci\u00f3n en Endocrinolog\u00eda, Nutrici\u00f3n y Diabetes 2019"],"award-info":[{"award-number":["BECA SENDIMAD de Ayuda a la Investigaci\u00f3n en Endocrinolog\u00eda, Nutrici\u00f3n y Diabetes 2019"]}]},{"name":"SENDIMAD","award":["BECA SENDIMAD de Ayuda a la Investigaci\u00f3n en Endocrinolog\u00eda, Nutrici\u00f3n y Diabetes 2019"],"award-info":[{"award-number":["BECA SENDIMAD de Ayuda a la Investigaci\u00f3n en Endocrinolog\u00eda, Nutrici\u00f3n y Diabetes 2019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12020-021-02704-2","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T10:02:56Z","timestamp":1617357776000},"page":"439-446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study"],"prefix":"10.1007","volume":"73","author":[{"given":"Mar\u00eda","family":"Fern\u00e1ndez-Arg\u00fceso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eider","family":"Pascual-Corrales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Bengoa Rojano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Garc\u00eda Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Jim\u00e9nez Mendiguch\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-0072","authenticated-orcid":false,"given":"Marta","family":"Araujo-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"key":"2704_CR1","doi-asserted-by":"publisher","first-page":"S0025-7753(20)3","DOI":"10.1016\/j.medcli.2020.04.029","volume":"22","author":"M Araujo-castro","year":"2020","unstructured":"M. Araujo-castro, Tratamiento del hiperaldosteronismo primario. Med Clin. 22, S0025-7753(20)30323-7 (2020). https:\/\/doi.org\/10.1016\/j.medcli.2020.04.029","journal-title":"Med Clin."},{"issue":"5","key":"2704_CR2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"J.W. Funder, R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101(5), 1889\u20131916 (2016). https:\/\/doi.org\/10.1210\/jc.2015-4061","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"2704_CR3","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, J.J. Mourad, Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45(8), 1243\u20131248 (2005). https:\/\/doi.org\/10.1016\/j.jacc.2005.01.015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"2704_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.tem.2005.02.010","volume":"16","author":"GP Rossi","year":"2005","unstructured":"G.P. Rossi, M. Boscaro, V. Ronconi, J.W. Funder, Aldosterone as a cardiovascular risk factor. Trends Endocrinol. Metab. 16(3), 104\u2013107 (2005). https:\/\/doi.org\/10.1016\/j.tem.2005.02.010","journal-title":"Trends Endocrinol. Metab."},{"issue":"10","key":"2704_CR5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/jhh.2010.65.","volume":"24","author":"Z \u0160oml\u00f3ov\u00e1","year":"2010","unstructured":"Z. \u0160oml\u00f3ov\u00e1, J. Widimsk\u00fd, J. Rosa, D. Wichterle, B. \u0160trauch, O. Petr\u00e1k et al. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. J. Hum. Hypertens. 24(10), 625\u2013630 (2010). https:\/\/doi.org\/10.1038\/jhh.2010.65.","journal-title":"J. Hum. Hypertens."},{"issue":"2","key":"2704_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","volume":"62","author":"S Savard","year":"2013","unstructured":"S. Savard, L. Amar, P.F. Plouin, O. Steichen, Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 62(2), 331\u2013336 (2013). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.01060","journal-title":"Hypertension"},{"issue":"4","key":"2704_CR7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1161\/HYPERTENSIONAHA.108.122002.","volume":"53","author":"J Matrozova","year":"2009","unstructured":"J. Matrozova, O. Steichen, L. Amar, S. Zacharieva, X. Jeunemaitre, P.F. Plouin, Fasting plasma glucose and serum lipids in patients with primary aldosteronism a controlled cross-sectional study. Hypertension 53(4), 605\u2013610 (2009). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.108.122002.","journal-title":"Hypertension"},{"issue":"5","key":"2704_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/BF03347840","volume":"18","author":"R Takeda","year":"1995","unstructured":"R. Takeda, T. Matsubara, I. Miyamori, H. Hatakeyama, T. Morise, Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J. Endocrinol. Invest 18(5), 370\u2013373 (1995). https:\/\/doi.org\/10.1007\/BF03347840","journal-title":"J. Endocrinol. Invest"},{"issue":"2","key":"2704_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/s0272-6386(99)70298-2","volume":"33","author":"M Nishimura","year":"1999","unstructured":"M. Nishimura, T. Uzu, T. Fujii, S. Kuroda, S. Nakamura, T. Inenaga et al. Cardiovascular complications in patients with primary aldosteronism. Am. J. Kidney Dis. 33(2), 261\u2013266 (1999). https:\/\/doi.org\/10.1016\/s0272-6386(99)70298-2","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"2704_CR10","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1161\/HYPERTENSIONAHA.117.10263","volume":"71","author":"Y Ohno","year":"2018","unstructured":"Y. Ohno, M. Sone, N. Inagaki, T. Yamasaki, O. Ogawa, Y. Takeda et al. Prevalence of Cardiovascular Disease And Its Risk Factors In Primary Aldosteronism A Multicenter Study in Japan. Hypertension 71(3), 530\u2013537 (2018). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.10263","journal-title":"Hypertension"},{"issue":"4","key":"2704_CR11","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1210\/jcem.85.4.6515","volume":"85","author":"R Rossi","year":"2000","unstructured":"R. Rossi, L. Tauchmanova, A. Luciano, M. Di Martino, C. Battista, L. Del Viscovo et al. Subclinical cushing\u2019s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J. Clin. Endocrinol. Metab. 85(4), 1440\u20131448 (2000). https:\/\/doi.org\/10.1210\/jcem.85.4.6515","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2 Suppl 1","key":"2704_CR12","first-page":"S1","volume":"39","author":"AS Levey","year":"2002","unstructured":"A.S. Levey, J. Coresh, K. Bolton, B. Culleton, K.S. Harvey, T.A. Ikizler et al. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 39(2 Suppl 1), S1\u2013266 (2002)","journal-title":"Am. J. Kidney Dis."},{"issue":"6","key":"2704_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.endinu.2020.03.002","volume":"67","author":"M Araujo-Castro","year":"2020","unstructured":"M. Araujo-Castro, M. Iturregui Guevara, M. Calatayud Guti\u00e9rrez, P. Parra Ram\u00edrez, P. Gracia Gimeno, F.A. Hanzu et al. Practical guide on the initial evaluation, follow-up, and treatment of adrenal incidentalomas adrenal diseases group of the Spanish society of endocrinology and nutrition. Endocrinol. Diabetes Nutr. 67(6), 408\u2013419 (2020). https:\/\/doi.org\/10.1016\/j.endinu.2020.03.002","journal-title":"Endocrinol. Diabetes Nutr."},{"issue":"3","key":"2704_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1530\/EJE-19-0047.","volume":"181","author":"A Kawashima","year":"2019","unstructured":"A. Kawashima, M. Sone, N. Inagaki, Y. Takeda, H. Itoh, I. Kurihara et al. Renal impairment is closely associated with plasma aldosterone concentration in patients with primary aldosteronism. Eur. J. Endocrinol. 181(3), 339\u2013350 (2019). https:\/\/doi.org\/10.1530\/EJE-19-0047.","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"2704_CR15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","volume":"48","author":"GP Rossi","year":"2006","unstructured":"G.P. Rossi, G. Bernini, G. Desideri, B. Fabris, C. Ferri, G. Giacchetti et al. Renal damage in primary aldosteronism: results of the PAPY study. Hypertension 48(2), 232\u2013238 (2006). https:\/\/doi.org\/10.1161\/01.HYP.0000230444.01215.6a","journal-title":"Hypertension"},{"issue":"6","key":"2704_CR16","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1210\/jc.2016-3867","volume":"102","author":"GL Hundemer","year":"2017","unstructured":"G.L. Hundemer, R. Baudrand, J.M. Brown, G. Curhan, G.H. Williams, A. Vaidya, Renin phenotypes characterize vascular disease, autonomous aldosteronism, and mineralocorticoid receptor activity. J. Clin. Endocrinol. Metab. 102(6), 1835\u20131843 (2017). https:\/\/doi.org\/10.1210\/jc.2016-3867","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"2704_CR17","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/HJH.0b013e328126855b","volume":"25","author":"LA Sechi","year":"2007","unstructured":"L.A. Sechi, M. Novello, R. Lapenna, S. Baroselli, E. Nadalini, G.L. Colussi et al. Long-term renal outcomes in patients with primary aldosteronism. J. Hypertens. 25(7), 1443\u20131450 (2007). https:\/\/doi.org\/10.1097\/HJH.0b013e328126855b","journal-title":"J. Hypertens."},{"issue":"3","key":"2704_CR18","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/jch.12914","volume":"19","author":"BJ Kramers","year":"2017","unstructured":"B.J. Kramers, C. Kramers, J.W.M. Lenders, J. Deinum, Effects of treating primary aldosteronism on renal function. J. Clin. Hypertens. 19(3), 290\u2013295 (2017). https:\/\/doi.org\/10.1111\/jch.12914","journal-title":"J. Clin. Hypertens."},{"issue":"4","key":"2704_CR19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2215\/CJN.00050107","volume":"2","author":"C Catena","year":"2007","unstructured":"C. Catena, G.L. Colussi, E. Nadalini, A. Chiuch, S. Baroselli, R. Lapenna et al. Relationships of plasma renin levels with renal function in patients with primary aldosteronism. Clin. J. Am. Soc. Nephrol. 2(4), 722\u2013731 (2007). https:\/\/doi.org\/10.2215\/CJN.00050107","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"5","key":"2704_CR20","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1681\/ASN.2004100878","volume":"16","author":"J Ribstein","year":"2005","unstructured":"J. Ribstein, G. Du Cailar, P. Fesler, A. Mimran, Relative glomerular hyperfiltration in primary aldosteronism. J. Am. Soc. Nephrol. 16(5), 1320\u20131325 (2005). https:\/\/doi.org\/10.1681\/ASN.2004100878","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"2704_CR21","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1210\/jc.2013-2180","volume":"99","author":"Y Iwakura","year":"2014","unstructured":"Y. Iwakura, R. Morimoto, M. Kudo, Y. Ono, K. Takase, K. Seiji et al. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J. Clin. Endocrinol. Metab. 99(5), 1593\u20131598 (2014). https:\/\/doi.org\/10.1210\/jc.2013-2180","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"2704_CR22","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","volume":"72","author":"GL Hundemer","year":"2018","unstructured":"G.L. Hundemer, G.C. Curhan, N. Yozamp, M. Wang, A. Vaidya, Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 72(3), 658\u2013666 (2018). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.11568","journal-title":"Hypertension"},{"issue":"6","key":"2704_CR23","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1210\/er.2018-00139.","volume":"39","author":"A Vaidya","year":"2018","unstructured":"A. Vaidya, P. Mulatero, R. Baudrand, G.K. Adler, The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr. Rev. 39(6), 1057\u20131088 (2018). https:\/\/doi.org\/10.1210\/er.2018-00139.","journal-title":"Endocr. Rev."},{"issue":"15-16","key":"2704_CR24","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.cca.2011.02.018","volume":"412","author":"VC Wu","year":"2011","unstructured":"V.C. Wu, S.Y. Yang, J.W. Lin, B.W. Cheng, C.C. Kuo, C.T. Tsai et al. Kidney impairment in primary aldosteronism. Clin. Chim. Acta 412(15-16), 1319\u20131325 (2011). https:\/\/doi.org\/10.1016\/j.cca.2011.02.018","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"2704_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/ki.1982.14","volume":"21","author":"RJ Hene","year":"1982","unstructured":"R.J. Hene, P. Boer, H.A. Koomans, E.J. Dorhout Mees, Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 21(1), 98\u2013101 (1982). https:\/\/doi.org\/10.1038\/ki.1982.14","journal-title":"Kidney Int."},{"issue":"3","key":"2704_CR26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/ki.2008.169","volume":"74","author":"A Levin","year":"2008","unstructured":"A. Levin, G.L. Bakris, M. Molitch, M. Smulders, J. Tian, L.A. Williams et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 74(3), 389\u2013390 (2008). https:\/\/doi.org\/10.1038\/ki.2008.169","journal-title":"Kidney Int."},{"issue":"1","key":"2704_CR27","doi-asserted-by":"publisher","first-page":"E75","DOI":"10.1210\/jc.2011-2183","volume":"97","author":"S Pilz","year":"2012","unstructured":"S. Pilz, K. Kienreich, C. Drechsler, E. Ritz, A. Fahrleitner-Pammer, M. Gaksch et al. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. Clin. Endocrinol. Metab. 97(1), E75\u2013E79 (2012). https:\/\/doi.org\/10.1210\/jc.2011-2183","journal-title":"Clin. Endocrinol. Metab."},{"issue":"2","key":"2704_CR28","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/HJH.0b013e32834f0451","volume":"30","author":"C Maniero","year":"2012","unstructured":"C. Maniero, A. Fassina, T.M. Seccia, A. Toniato, M. Iacobone, M. Plebani et al. Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. J. Hypertens. 30(2), 390\u2013395 (2012). https:\/\/doi.org\/10.1097\/HJH.0b013e32834f0451","journal-title":"J. Hypertens."},{"issue":"1","key":"2704_CR29","doi-asserted-by":"publisher","first-page":"H286","DOI":"10.1152\/ajpheart.00535.2005","volume":"290","author":"A Vidal","year":"2006","unstructured":"A. Vidal, Y. Sun, S.K. Bhattacharya, R.A. Ahokas, I.C. Gerling, K.T. Weber, Calcium paradox of aldosteronism and the role of the parathyroid glands. Am. J. Physiol. Heart Circ. Physiol. 290(1), H286\u2013H294 (2006). https:\/\/doi.org\/10.1152\/ajpheart.00535.2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"2","key":"2704_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1161\/HYPERTENSIONAHA.113.01910","volume":"63","author":"JM Brown","year":"2014","unstructured":"J.M. Brown, J.S. Williams, J.M. Luther, R. Garg, A.E. Garza, L.H. Pojoga et al. Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone. Hypertension 63(2), 273\u2013280 (2014). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.01910","journal-title":"Hypertension"},{"issue":"9","key":"2704_CR31","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1210\/jc.2019-00143","volume":"104","author":"L Lenzini","year":"2019","unstructured":"L. Lenzini, S. Prisco, P.E. Vanderriele, S. Lerco, F. Torresan, G. Maiolino et al. PTH modulation by aldosterone and angiotensin II is blunted in hyperaldosteronism and rescued by adralectomy. J. Clin. Endocrinol. Metab. 104(9), 3726\u20133734 (2019). https:\/\/doi.org\/10.1210\/jc.2019-00143","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"2704_CR32","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1210\/jc.2008-2116.","volume":"94","author":"E Born-Frontsberg","year":"2009","unstructured":"E. Born-Frontsberg, M. Reincke, L.C. Rump, S. Hahner, S. Diederich, R. Lorenz et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German conn\u2019s registry. J. Clin. Endocrinol. Metab. 94(4), 1125\u20131130 (2009). https:\/\/doi.org\/10.1210\/jc.2008-2116.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"2704_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"S. Monticone, F. D\u2019Ascenzo, C. Moretti, T.A. Williams, F. Veglio, F. Gaita et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 6(1), 41\u201350 (2018). https:\/\/doi.org\/10.1016\/S2213-8587(17)30319-4","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"2704_CR34","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1210\/jc.2008-1851","volume":"94","author":"M Reincke","year":"2009","unstructured":"M. Reincke, L.C. Rump, M. Quinkler, S. Hahner, S. Diederich, R. Lorenz et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J. Clin. Endocrinol. Metab. 94(3), 869\u2013875 (2009). https:\/\/doi.org\/10.1210\/jc.2008-1851","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"2704_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","volume":"66","author":"NK Hollenberg","year":"2004","unstructured":"N.K. Hollenberg, Aldosterone in the development and progression of renal injury. Kidney Int. 66(1), 1\u20139 (2004). https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00701.x","journal-title":"Kidney Int."},{"issue":"7","key":"2704_CR36","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/s1043-2760(01)00432-5.","volume":"12","author":"R Rocha","year":"2001","unstructured":"R. Rocha, C.T. Stier, Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol. Metab. 12(7), 308\u2013314 (2001). https:\/\/doi.org\/10.1016\/s1043-2760(01)00432-5.","journal-title":"Trends Endocrinol. Metab."},{"issue":"12 Pt 2","key":"2704_CR37","first-page":"1801","volume":"13","author":"H Jean-Michel","year":"1995","unstructured":"H. Jean-Michel, A. Mimran, Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J. Hypertens. 13(12 Pt 2), 1801\u20131802 (1995)","journal-title":"J. Hypertens."},{"issue":"9","key":"2704_CR38","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1210\/jcem.85.9.6819","volume":"85","author":"W Oelkers","year":"2000","unstructured":"W. Oelkers, S. Diederich, V. B\u00e4hr, Primary hyperaldosteronism without suppressed renin due to secondary hypertensive kidney damage. J. Clin. Endocrinol. Metab. 85(9), 3266\u20133270 (2000). https:\/\/doi.org\/10.1210\/jcem.85.9.6819","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"2704_CR39","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/ijms18020294","volume":"18","author":"A Kot\u0142owska","year":"2017","unstructured":"A. Kot\u0142owska, T. Puzyn, K. Sworczak, P. Stepnowski, P. Szefer, Metabolomic biomarkers in urine of cushing\u2019s syndrome patients. Int J. Mol. Sci. 18(2), 294 (2017). https:\/\/doi.org\/10.3390\/ijms18020294","journal-title":"Int J. Mol. Sci."},{"issue":"10","key":"2704_CR40","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.metabol.2010.01.007","volume":"59","author":"M Peppa","year":"2010","unstructured":"M. Peppa, E. Boutati, C. Koliaki, N. Papaefstathiou, E. Garoflos, T. Economopoulos et al. Insulin resistance and metabolic syndrome in patients with nonfunctioning adrenal incidentalomas: a cause-effect relationship? Metabolism 59(10), 1435\u20131441 (2010). https:\/\/doi.org\/10.1016\/j.metabol.2010.01.007","journal-title":"Metabolism"},{"issue":"3","key":"2704_CR41","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s12020-019-02066-w","volume":"66","author":"M Araujo-Castro","year":"2019","unstructured":"M. Araujo-Castro, C. Robles L\u00e1zaro, P. Parra Ram\u00edrez, M. Cuesta Hern\u00e1ndez, M.A. Sampedro N\u00fa\u00f1ez, M. Marazuela, Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences? Endocrine 66(3), 650\u2013659 (2019). https:\/\/doi.org\/10.1007\/s12020-019-02066-w","journal-title":"Endocrine"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02704-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02704-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02704-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T14:42:11Z","timestamp":1625668931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02704-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["2704"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02704-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-238982\/v1","asserted-by":"object"}]},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,2]]},"assertion":[{"value":"13 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in the participants of the study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable (Ethical Commit has approved the exemption of informed consent due to the observational and retrospective nature of the study, with any risk for the patients included).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}